Key result
The ApoB/A1 ratio was independently associated with an increased risk of major adverse cardiovascular events (HR 1.12 per 0.1 increase) in patients with coronary artery disease undergoing PCI.
Why the study?
The ApoB/A1 ratio has emerged as a superior lipid marker, prompting the development and validation of a predictive nomogram for MACE in CAD patients undergoing PCI.
Does the ApoB/A1 ratio and a derived nomogram predict major adverse cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention?
Population
2459 CAD patients undergoing PCI
Comparison
ApoB/A1 ratio levels and nomogram-based risk stratification
Design
Retrospective cohort study
Follow-up
Median of 33.8 months
Authors
Loading...
Should not change practice for MACE risk stratification; leaves open causality and therapeutic relevance of ApoB/A1 ratio.
Cohort (n=2,459)
No
Does the ApoB/A1 ratio and a derived nomogram predict major adverse cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention?
Effect estimate: HR 1.12 (95% CI 1.06-1.19)
p-value: p=<0.001
The ApoB/A1 ratio is an independent predictor of MACE in CAD patients post-PCI, and a nomogram incorporating this ratio provides effective risk stratification.
Zhu et al. (2026) conducted a cohort in Coronary artery disease undergoing percutaneous coronary intervention (n=2,459). Apolipoprotein B/A1 Ratio was evaluated on Major adverse cardiovascular events (MACE) (HR 1.12, 95% CI 1.06-1.19, p=<0.001). The ApoB/A1 ratio was independently associated with an increased risk of major adverse cardiovascular events (HR 1.12 per 0.1 increase) in patients with coronary artery disease undergoing PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: